Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 982504, 8 pages
http://dx.doi.org/10.1155/2014/982504
Research Article

Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

1Hematology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, #222 Banpo-daero, Seocho-Gu, Seoul 137-701, Republic of Korea
2Department of Laboratory Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea

Received 20 February 2014; Accepted 18 April 2014; Published 6 May 2014

Academic Editor: Dong Soon Lee

Copyright © 2014 Sung-Eun Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Blade, D. Samson, D. Reece et al., “Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant,” British Journal of Haematology, vol. 102, no. 5, pp. 1115–1123, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. R. A. Kyle and S. V. Rajkumar, “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma,” Leukemia, vol. 23, no. 1, pp. 3–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. V. Rajkumar, R. Fonseca, A. Dispenzieri et al., “Effect of complete response on outcome following autologous stem cell transplantation for myeloma,” Bone Marrow Transplantation, vol. 26, no. 9, pp. 979–983, 2000. View at Google Scholar · View at Scopus
  4. S. V. Rajkumar, R. Fonseca, M. Q. Lacy et al., “Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma,” Bone Marrow Transplantation, vol. 23, no. 12, pp. 1261–1266, 1999. View at Google Scholar · View at Scopus
  5. J. S. Kim, K. Kim, J. Cheong et al., “Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation,” Biology of Blood and Marrow Transplantation, vol. 15, no. 4, pp. 463–470, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Lee, S. Yahng, B. Cho et al., “Lymphocyte subset analysis for the assessment of treatment-related complications after autologous stem cell transplantation in multiple myeloma,” Cytotherapy, vol. 14, no. 4, pp. 505–512, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. B. G. M. Durie, J.-L. Harousseau, J. S. Miguel et al., “International uniform response criteria for multiple myeloma,” Leukemia, vol. 20, no. 9, pp. 1467–1473, 2006. View at Google Scholar
  8. K. Elenius and L. Jalkanen, “Function of the syndecans—a family of cell surface proteoglycans,” Journal of Cell Science, vol. 107, no. 11, pp. 2975–2982, 1994. View at Google Scholar · View at Scopus
  9. R. C. Ridley, H. Xiao, H. Hata, J. Woodliff, J. Epstein, and R. D. Sanderson, “Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen,” Blood, vol. 81, no. 3, pp. 767–774, 1993. View at Google Scholar · View at Scopus
  10. F. P. O'Connell, J. L. Pinkus, and G. S. Pinkus, “CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms,” American Journal of Clinical Pathology, vol. 121, no. 2, pp. 254–263, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. F. DiPersio, A. D. Ho, J. Hanrahan, F. J. Hsu, and S. Fruehauf, “Relevance and clinical implications of tumor cell mobilization in the autologous transplant setting,” Biology of Blood and Marrow Transplantation, vol. 17, no. 7, pp. 943–955, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. H. G. Kopp, S. Yildirim, K. C. Weisel, L. Kanz, and W. Vogel, “Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma,” Journal of Cancer Research and Clinical Oncology, vol. 135, no. 4, pp. 637–642, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. A. K. Stewart, R. Vescio, G. Schiller et al., “Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial,” Journal of Clinical Oncology, vol. 19, no. 17, pp. 3771–3779, 2001. View at Google Scholar · View at Scopus
  14. M. Putkonen, V. Kairisto, V. Juvonen et al., “Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma,” European Journal of Haematology, vol. 85, no. 5, pp. 416–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Paiva, M. Vidriales, J. Cerveró et al., “Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation,” Blood, vol. 112, no. 10, pp. 4017–4023, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. H. J. K. van de Velde, X. Liu, G. Chen, A. Cakana, W. Deraedt, and M. Bayssas, “Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma,” Haematologica, vol. 92, no. 10, pp. 1399–1406, 2007. View at Publisher · View at Google Scholar · View at Scopus